TY - JOUR
T1 - European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1
T2 - Diagnostics and prevention-Update 2023
AU - Stratigos, Alexander J
AU - Garbe, Claus
AU - Dessinioti, Clio
AU - Lebbe, Celeste
AU - van Akkooi, Alexander
AU - Bataille, Veronique
AU - Bastholt, Lars
AU - Dreno, Brigitte
AU - Dummer, Reinhard
AU - Fargnoli, Maria Concetta
AU - Forsea, Ana Maria
AU - Harwood, Catherine A
AU - Hauschild, Axel
AU - Hoeller, Christoph
AU - Kandolf-Sekulovic, Lidija
AU - Kaufmann, Roland
AU - Kelleners-Smeets, Nicole Wj
AU - Lallas, Aimilios
AU - Leiter, Ulrike
AU - Malvehy, Josep
AU - Del Marmol, Veronique
AU - Moreno-Ramirez, David
AU - Pellacani, Giovanni
AU - Peris, Ketty
AU - Saiag, Philippe
AU - Tagliaferri, Luca
AU - Trakatelli, Myrto
AU - Ioannides, Dimitrios
AU - Vieira, Ricardo
AU - Zalaudek, Iris
AU - Arenberger, Petr
AU - Eggermont, Alexander M M
AU - Röcken, Martin
AU - Grob, Jean-Jacques
AU - Lorigan, Paul
AU - EADO, EDF, ESTRO, UEMS, EADV and EORTC
PY - 2023/7/28
Y1 - 2023/7/28
N2 - Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in white populations, accounting for 20% of all cutaneous malignancies. Overall, cSCC mostly has very good prognosis after treatment, with 5-year cure rates greater than 90%. Despite the overall favourable prognosis and the proportionally rare deaths, cSCC is associated with a high total number of deaths due to its high incidence. A collaboration of multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV) and the European Organization of Research and Treatment of Cancer (EORTC), was formed to update recommendations on cSCC, based on current literature and expert consensus. Part 1 of the guidelines addresses the updates on classification, epidemiology, diagnosis, risk stratification, staging and prevention in immunocompetent as well as immunosuppressed patients.
AB - Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in white populations, accounting for 20% of all cutaneous malignancies. Overall, cSCC mostly has very good prognosis after treatment, with 5-year cure rates greater than 90%. Despite the overall favourable prognosis and the proportionally rare deaths, cSCC is associated with a high total number of deaths due to its high incidence. A collaboration of multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV) and the European Organization of Research and Treatment of Cancer (EORTC), was formed to update recommendations on cSCC, based on current literature and expert consensus. Part 1 of the guidelines addresses the updates on classification, epidemiology, diagnosis, risk stratification, staging and prevention in immunocompetent as well as immunosuppressed patients.
KW - Advanced
KW - Diagnosis
KW - High-risk
KW - Immunosuppression
KW - Invasive cutaneous squamous cell carcinoma
KW - Locally advanced cSCC
KW - Metastatic cSCC
KW - Prevention
KW - Prognosis
KW - Staging
U2 - 10.1016/j.ejca.2023.113251
DO - 10.1016/j.ejca.2023.113251
M3 - Article
SN - 0959-8049
VL - 193
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 1
M1 - 113251
ER -